Unknown

Dataset Information

0

Evolution of delayed resistance to immunotherapy in a melanoma responder.


ABSTRACT: Despite initial responses1-3, most melanoma patients develop resistance4 to immune checkpoint blockade (ICB). To understand the evolution of resistance, we studied 37 tumor samples over 9 years from a patient with metastatic melanoma with complete clinical response to ICB followed by delayed recurrence and death. Phylogenetic analysis revealed co-evolution of seven lineages with multiple convergent, but independent resistance-associated alterations. All recurrent tumors emerged from a lineage characterized by loss of chromosome 15q, with post-treatment clones acquiring additional genomic driver events. Deconvolution of bulk RNA sequencing and highly multiplexed immunofluorescence (t-CyCIF) revealed differences in immune composition among different lineages. Imaging revealed a vasculogenic mimicry phenotype in NGFRhi tumor cells with high PD-L1 expression in close proximity to immune cells. Rapid autopsy demonstrated two distinct NGFR spatial patterns with high polarity and proximity to immune cells in subcutaneous tumors versus a diffuse spatial pattern in lung tumors, suggesting different roles of this neural-crest-like program in different tumor microenvironments. Broadly, this study establishes a high-resolution map of the evolutionary dynamics of resistance to ICB, characterizes a de-differentiated neural-crest tumor population in melanoma immunotherapy resistance and describes site-specific differences in tumor-immune interactions via longitudinal analysis of a patient with melanoma with an unusual clinical course.

SUBMITTER: Liu D 

PROVIDER: S-EPMC8474080 | biostudies-literature | 2021 Jun

REPOSITORIES: biostudies-literature

altmetric image

Publications

Evolution of delayed resistance to immunotherapy in a melanoma responder.

Liu David D   Lin Jia-Ren JR   Robitschek Emily J EJ   Kasumova Gyulnara G GG   Heyde Alex A   Shi Alvin A   Kraya Adam A   Zhang Gao G   Moll Tabea T   Frederick Dennie T DT   Chen Yu-An YA   Wang Shu S   Schapiro Denis D   Ho Li-Lun LL   Bi Kevin K   Sahu Avinash A   Mei Shaolin S   Miao Benchun B   Sharova Tatyana T   Alvarez-Breckenridge Christopher C   Stocking Jackson H JH   Kim Tommy T   Fadden Riley R   Lawrence Donald D   Hoang Mai P MP   Cahill Daniel P DP   Malehmir Mohsen M   Nowak Martin A MA   Brastianos Priscilla K PK   Lian Christine G CG   Ruppin Eytan E   Izar Benjamin B   Herlyn Meenhard M   Van Allen Eliezer M EM   Nathanson Katherine K   Flaherty Keith T KT   Sullivan Ryan J RJ   Kellis Manolis M   Sorger Peter K PK   Boland Genevieve M GM  

Nature medicine 20210503 6


Despite initial responses<sup>1-3</sup>, most melanoma patients develop resistance<sup>4</sup> to immune checkpoint blockade (ICB). To understand the evolution of resistance, we studied 37 tumor samples over 9 years from a patient with metastatic melanoma with complete clinical response to ICB followed by delayed recurrence and death. Phylogenetic analysis revealed co-evolution of seven lineages with multiple convergent, but independent resistance-associated alterations. All recurrent tumors eme  ...[more]

Similar Datasets

| PRJEB45846 | ENA
| S-EPMC11021475 | biostudies-literature
| S-EPMC9066268 | biostudies-literature
| S-EPMC7864871 | biostudies-literature
| S-EPMC7864867 | biostudies-literature
2024-12-04 | GSE274229 | GEO
| S-EPMC11779626 | biostudies-literature
| S-EPMC8023145 | biostudies-literature
| S-EPMC10051223 | biostudies-literature
| S-EPMC4049781 | biostudies-literature